Dialysis vintage and outcomes after kidney transplantation: A retrospective cohort study

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 1, 2017, Pages 122-130

  Haller, Maria C ^a,b,c   Kainz, Alexander ^a   Baer, Heather ^d,e,f   Oberbauer, Rainer ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b ELISABETHINEN HOSPITAL   (Austria)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Allografts; Chronic dialysis; Cohort studies; Death; Follow up studies; Graft survival; Humans; Kidney transplantation; Liver transplantation; Outcomes; Registries; Renal dialysis; Renal replacement therapy; Retrospective studies; Tissue donors; Transplantation

Indexed keywords

ARTICLE; CHILD; COHORT ANALYSIS; DIALYSIS; FEMALE; FOLLOW UP; GRAFT FAILURE; HUMAN; KIDNEY TRANSPLANTATION; MALE; MORTALITY; RETROSPECTIVE STUDY; SCHOOL CHILD; ADULT; AGED; CHRONIC KIDNEY FAILURE; GRAFT SURVIVAL; HEMODIALYSIS; HOSPITAL ADMISSION; KAPLAN MEIER METHOD; MIDDLE AGED; PREOPERATIVE PERIOD; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MORTALITY; PREOPERATIVE PERIOD; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; WAITING LISTS; YOUNG ADULT;

EID: 85020500772     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.04120416     Document Type: Article

References (40)

1. Haller M, Gutjahr G, Kramar R, Harnoncourt F, Oberbauer R: Cost-effectiveness analysis of renal replacement therapy in Austria. Nephrol Dial Transplant 26: 2988–2995, 2011
2. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: A systematic review and modelling study. Health Technol Assess 9: 1–1792005
3. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK: Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341: 17251730, 1999
4. Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong AWebster AC, Craig JC: Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis people with varying ages and co-morbidities. PLoS One 7: e29591, 2012
5. Rabbat CG, Thorpe KE, Russell JD, Churchill DN: Comparison mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 11917–922, 2000
6. Merion RM, Ashby VB, Wolfe RA, Distant DA, Hulbert-Shearon TE, Metzger RA, Ojo AO, Port FK: Deceased-donor characteristics and the survival benefit of kidney transplantation. JAMA 2942726–2733, 2005
7. Vollmer WM, Wahl PW, Blagg CR: Survival with dialysis and transplantation in patients with end-stage renal disease. NEnglMed 308: 1553–1558, 1983
8. Schnuelle P, Lorenz D, Trede M, Van Der Woude FJ: Impact of renal cadaveric transplantation on survival in end-stage renal failure: Evidence for reduced mortality risk compared with hemodialysis during long-term follow-up. J Am Soc Nephrol 9: 2135–2141, 1998
9. Cosio FG, Alamir A, Yim S, Pesavento TE, Falkenhain ME, Henr ML, Elkhammas EA, Davies EA, Bumgardner GL, Ferguson RM: Patient survival after renal transplantation: I. The impact of dialysis pre-transplant. Kidney Int 53: 767–772, 1998
10. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, Leichtman AB, Kaplan B: Effect of waiting time on renal transplant outcome. Kidney Int 58: 1311–1317, 2000
11. Meier-Kriesche HU, Kaplan B: Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: A paired donor kidney analysis. Transplantation 74: 1377– 1381, 2002
12. Mange KC, Joffe MM, Feldman HI: Effect of the use or nonuse of long-term dialysis on the subsequent survival of renal transplants from living donors. N Engl J Med 344: 726–731, 2001
13. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB, Merion RM, Metzger RA, Pradel F, Schweitzer EJ, Velez RL, Gaston RS: Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol 3: 471–480, 2008
14. Abramowicz D, Hazzan M, Maggiore U, Peruzzi L, Cochat P, Oberbauer R, Haller M, Van Biesen W; Descartes Working Group and the European Renal Best Practice (ERBP) Advisory Board: Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes working group and ERBP. Nephrol Dial Transplant 31: 691–697, 2015
15. ERA-EDTA Registry, AMC, Department of Medical Informatics, Amsterdam, The Netherlands: ERA-EDTA Registry Annual Report 2012. 2014
16. U.S. Renal Data System: USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD, NIoH, National Institute of Diabetes and Digestive and Kidney Diseases, 2013
17. ANZDATA Registry: 38th Report, Chapter 3: Mortality in End Stage Kidney Disease. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, Australia. 2016. Available at: http://www.anzdata.org.au. Accessed November 17, 2015
18. Halloran PF: Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715–2729, 2004
19. Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G: Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323, 2005
20. Masson P, Henderson L, Chapman JR, Craig JC, Webster AC: Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 11: CD010699, 2014
21. Helantera I, Salmela K, Kyllonen L, Koskinen P, Gronhagen-Riska C, Finne P: Pretransplant dialysis duration and risk of death after kidney transplantation in the current era. Transplantation 98: 458–464, 2014
22. Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R: Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17: 889–899, 2006
23. Heinze G, Kainz A, Hörl WH, Oberbauer R: Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ 339: b4018, 2009
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J AmStat Assoc 53: 457–481, 1958
25. Cox D: Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34: 187–220, 1972
26. Fine JP, Gray RJ: A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc 94: 496–509, 1999
27. Bursac Z, Gauss CH, Williams DK, Hosmer DW: Purposeful selection of variables in logistic regression. Source Code Biol Med 3: 17, 2008
28. Yabu JM, Anderson MW, Kim D, Bradbury BD, Lou CD, Petersen J, Rossert J, Chertow GM, Tyan DB: Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant 28: 2908–2918, 2013
29. Scornik JC, Meier-Kriesche HU: Blood transfusions in organ transplant patients: Mechanisms of sensitization and implications for prevention. Am J Transplant 11: 1785–1791, 2011
30. Heidt S, Witvliet MD, Haasnoot GW, Claas FH: The 25th anniversary of the Eurotransplant acceptable mismatch program for highly sensitized patients. Transpl Immunol 33: 51–57, 2015
31. Konvalinka A, Tinckam K: Utility of HLA antibody testing in kidney transplantation. J AmSoc Nephrol 26: 1489–1502, 2015
32. Organ Procurement and Transplantation Network (OPTN): Available at http://optn.transplant.hrsa.gov/learn/professional-education/kidney-allocation-system/. Accessed November 172015
33. Marfo K, Lu A, Ling M, Akalin E: Desensitization protocols and their outcome. Clin J Am Soc Nephrol 6: 922–936, 2011
34. Chinen J, Buckley RH: Transplantation immunology: Solid organ and bone marrow. J Allergy Clin Immunol 125: S324–S335, 2010
35. Webster AC, Ruster LP, McGee R, Matheson SL, Higgins GY, Willis NS, Chapman JR, Craig JC: Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database SysRev 1:CD003897, 2010
36. Ojo AO, Morales JM, González-Molina M, Steffick DE, Lua FL, Merion RM, Ojo T, Moreso F, Arias M, Campistol JM, Hernandez D, Serón D; Scientific Registry of Transplant Recipients and; Spanish Chronic Allograft Study Group: Comparison of the long-term outcomes of kidney transplantation: USA versus Spain. Nephrol Dial Transplant 28: 213–220, 2013
37. Schold JD, Sehgal AR, Srinivas TR, Poggio ED, Navaneethan SD, Kaplan B: Marked variation of the association of ESRD duration before and after wait listing on kidney transplant outcomes. Am J Transplant 10: 2008–2016, 2010
38. World Bank: World Development Indicators 2015. Washington, DC, World Bank, 2015
39. Heinze G, Oberbauer R: Does size matter? Nephrol Dial Transplant 22: 2725–2726, 2007
40. Keith DS: Preemptive deceased donor kidney transplant not associated with patient survival benefit in minority kidney transplant recipients. Clin Transplant 26: 82–86, 2012